AstraZeneca Pharma India Ltd. — Board/Management Information 2022

Aug 10, 2022

==> picture [571 x 82] intentionally omitted <==

August 10, 2022

The Manager ‐ Listing

National Stock Exchange of India Ltd. Exchange plaza, 5[th] Floor, Plot No. C/1, G Block Bandra‐Kurla Complex, Bandra (E), Mumbai 400051

The Manager ‐ Listing BSE Limited Corporate Relationship Dept., 1[st] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 400001

Dear Sir(s),

Sub: Appointment of Director at Annual General Meeting held on August 8, 2022

In continuation of our earlier announcement dated December 30, 2021., we wish to inform you that at the Company’s Annual General Meeting held on August 8, 2022, the Shareholders have approved the appointment of Ms. Shilpa Shridhar Divekar, as an Independent Director for a term of 5 years with effect from December 29, 2021 till December 28, 2026.

The requisite details of the appointment pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular dated September 9, 2015, are given as Annexure A.

We request you to please take the same on record.

Thanking you,

Yours faithfully

For AstraZeneca Pharma India Limited

BHUVANAG Digitally signed by BHUVANAGIRI IRI RUDRA RUDRA PRATAP PRATAP Date: 2022.08.10 14:33:44 +05'30'

Pratap Rudra Company Secretary & Legal Counsel

Annexure A

Sl.No		Particulars	Details
1		Reason for change Viz. appointment, ~~resignation,~~ ~~removal, death or otherwise~~	Appointment of Ms. Shilpa Shridhar Divekar as a Non‐ Executive & Independent Director.
2		Date of Appointment/ ~~Cessation/T~~erm of appointment	Five years commencing from December 29, 2021, as per the resolution passed by shareholders of the Companyat the AGM dated August 8,2022.
3		Brief Profile	Ms. Shilpa Shridhar Divekar has over two decades of rich experience across consulting and food & agriculture sectors. As part of her leadership journey, she led Regional Business Strategy for Asia Pacific and co‐led Global Smallholder Strategy at Bayer CropScience. She served as the Chief Executive Officer of Monsanto India from 2014 to 2018 and was also responsible as Managing Director of the publicly listed entity in India. Prior to her 12 years stint at Bayer and Monsanto, she was the Head of Strategy & Business Development for Bunge India, a US headquartered multinational involved in oilseeds, commodity trading & foods. She started her career journey in 1996 at Arthur Andersen and KPMG, and gained significant experience serving clients in diverse industry sectors. Since April 2020, she has chosen to be a mentor to businesses seeking to turnaround, grow or start‐up. In 2017, she was recognised among the Top 50 Most Powerful Women Leaders by Fortune India. She holds a Master in Business Administration from S. P. Jain Institute of Management & Research and she is a Chartered Accountant and Cost & Works Accountant.
4		Disclosure of Relationships between Directors	Ms. Shilpa Shridhar Divekar is not related to any of the Directors of the Company.
5		Affirmation pursuant to circular no. LIST/COMP/14/2018‐19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE	Ms. Shilpa Shridhar Divekar is not debarred from holding the office of Director by virtue of any SEBI Order or any such Authority.